Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 24 Late-Breaking Discussion: The ZODIAC Trial
Author(s): Harriette Van Spall , Kausik Ray Added: 7 months ago
AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising… View more

Prevention & Chronic Conditions

MI/ACS
Author(s): Evan A Stein Added: 1 year ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions
PCSK9 Inhibition: The Big Step Forward in Lipid Control
Author(s): Rishi Rikhi , Michael D Shapiro Added: 2 years ago

Vascular Disease and Surgery

Prevention & Chronic Conditions
Advancements in Triglyceride-lowering Therapies
Author(s): , Added: 10 months ago
In this video series, recorded at ESC 2024 in London, Prof Gerald Watts (University of Western Australia, Perth, Australia) is joined by Prof Robert S Rosenson (Mount Sinai Icahn School of Medicine, New York, US) to discuss developments in triglyceride-lowering therapies.The faculty consider triglycerides as a risk factor for cardiovascular disease and explore the relationship between… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Managing Hyperkalaemia: Getting Patients to Optimal RAASi Therapy
Author(s): James Burton , Clara Bonanad Lozano , Aaron Wong , et al Start date: Jul 02, 2025
.img-row:after { content: ""; clear: both; display: table; } .img-column { float: left; width: 50%; padding: 5px; } @media screen and (max-width: 500px) { .img-column { width: 100%; } } Join James Burton (University of Leicester, Leicester, UK), Clara Bonanad (University Clinical Hospital of Valencia, Valencia, ES), Aaron Wong (Princess of Wales Hospital, Bridgend, Wales, UK)… View more

Cardiovascular Renal Metabolic

Heart Failure
Ablation as First-line Therapy for Atrial Fibrillation.
Author(s): Jason G Andrade Added: 1 year ago

Electrophysiology & Arrhythmia
Tricuspid Regurgitation Therapy
Author(s): Qiuyu Martin Zhu , Natalia Berry Added: 1 year ago

Heart Failure
SCAI 25: Insights from the TRITAVI Registry
Author(s): Francesco Pelliccia Added: 2 months ago
SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights… View more

Anticoagulation

Intervention
AHA 23: SUPER LIPID
Author(s): Alexander Fanaroff Added: 1 year ago
AHA 2023 — We are joined by Dr Alexander Fanaroff (Penn Medicine, US) to discuss the findings from a cluster randomised trial of automated referral to centralised pharmacy services for evidence-based statin initiation in high-risk patients.Gaps have been observed in evidence-based statin prescriptions, where more than 50% of US adults with an indication for atherosclerotic cardiovascular disease… View more

Prevention & Chronic Conditions
Atorvastatin and Ezetimibe in Patients with Acute Coronary Syndrome
Author(s): Mohammed Sallam , Hossameldin Hassan , Derek Connolly , et al Added: 7 months ago

Prevention & Chronic Conditions

MI/ACS